KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Invested Capital (2023 - 2025)

Recursion Pharmaceuticals' Return on Invested Capital history spans 3 years, with the latest figure at 0.59% for Q4 2025.

  • For Q4 2025, Return on Invested Capital rose 2.0% year-over-year to 0.59%; the TTM value through Dec 2025 reached 0.59%, up 2.0%, while the annual FY2025 figure was 0.59%, 4.0% up from the prior year.
  • Return on Invested Capital reached 0.59% in Q4 2025 per RXRX's latest filing, up from 0.73% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.58% in Q1 2025 to a low of 0.86% in Q1 2024.
  • Average Return on Invested Capital over 3 years is 0.7%, with a median of 0.69% recorded in 2025.
  • The largest YoY upside for Return on Invested Capital was 28bps in 2025 against a maximum downside of -4bps in 2025.
  • A 3-year view of Return on Invested Capital shows it stood at 0.77% in 2023, then increased by 21bps to 0.61% in 2024, then grew by 3bps to 0.59% in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Return on Invested Capital are 0.59% (Q4 2025), 0.73% (Q3 2025), and 0.69% (Q2 2025).